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Legacy data stores of experimental assay data in a pharmaceutical R&D organization are 
poorly structured and annotated, which hinders the integration of these data with data 
from more recent research programs and from other publicly available clinical, biological 
and chemical data sources. Being able to integrate and analyze this data in aggregate will 
help maximize the value of the available data, which will help inform and potentially 
improve the drug discovery process.  
In this study, text mining and information extraction tools and techniques were applied to 
improve the annotation of a subset of these data in an accurate and automated fashion.  
Experimental results of this study show promise for classifying some features of the 
available assay data. Initial results of classification using a Naïve-Bayes classifier 
provided high values of accuracy (upto 93%). This indicates that the methods described 
in this study can be extended to larger dataset to extract more annotation from the 
available data. 
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1. Introduction: 
Research oriented companies in a wide variety of fields often have large stores of data 
from legacy research programs that are poorly structured and annotated. As a 
consequence these data stores are poorly integrated with other data from more recent 
research programs or with data from external sources. This results in the companies not 
being able to analyze these data in aggregate, thus having poor access to critical 
experimental information. 
Groups involved in the early discovery phase of drug development
1
 in pharmaceutical 
organizations generate a large amount of pharmaceutical assay data. 
An Assay is defined as  
“An investigative (analytic) procedure in laboratory 
medicine, pharmacology, environmental biology, and molecular biology for qualitatively 
assessing or quantitatively measuring the presence or amount or the functional activity of 
a target entity (the analyte) which can be a drug or biochemical substance or a cell in 
an organism or organic sample” (Assay, 2014).  
The endpoint of an assay is the activity of a biological macromolecule, often referred 
to as the target of the assay. Figure 1 describes a standard drug discovery progression 
path. Compounds are screened for activity against a particular target. 
                                                          
1
 Drug development is the process of bringing a new drug to the market once a lead component has 
been identified through drug discovery. Drug discovery is the process by which new candidate medications 
are discovered 
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These target centric primary assays can be conducted in either cell-based or cell-free 
media or other physiochemical assays that measure the chemical developability of the 
molecule. The chemical developability refers to the presence of chemical properties 
necessary for the molecule to be developed into a drug. An example of a physiochemical 
assay is the measurement of the solubility or the purity of the compound in simulated 
intestinal fluid. 
 This is followed by cell-based secondary assays that measure phenotypes
2
 that are 
thought to be relevant to a disease. In-vivo experiments are then conducted to observe 
pharmacokinetics
3
 which reflect how much of the compound is absorbed, whether it gets 
to the target tissue and whether it produces the desired effect. The information from these 
studies is used to progress with compounds that have sufficient pharmacokinetics, and as 
input to design efficacy
4
 studies. The efficacy studies are followed by safety studies to 
characterize at what doses the compound is safe. These stages form the pre-clinical phase 
of drug development.
                                                          
2
 Phenotypes – observable characteristics or traits. 
3
 Pharmacokinetics – Study of time and course of drug absorption, distribution, metabolism and 
excretion. 
4
 Efficacy – Maximum response achievable from a drug/compound 
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Figure 1: Drug Discovery Progression Path 
Drug discovery has historically proven to be a lengthy, expensive and inefficient 
process. Any time a compound fails one step, the process has to be restarted. The farther 
down the path a compound fails, the higher the costs involved.  
A variety of cell biology, genetic and other experiments are conducted to pick a target 
that might be relevant to a particular disease, but target selection is an imperfect science. 
The therapeutic rationale behind a target might fail for a number of reasons. For example, 
if key experiments were performed using animal tissues or in an animal, it might not 
translate well to humans. It is not uncommon to find compounds that show efficacy, but 
present adverse findings in toxicity studies preventing its progression. Even when a safe 
and efficacious compound is identified for disease intervention, the compound might 
affect other biological activities, which is unacceptable irrespective of the benefits 
offered. For example, acne medication causing severe diarrhea is not acceptable. Years of 
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effort from many researchers can be spent if these liabilities are not discovered early in 
the progression path.  
The goal of every drug discovery team is to identify compounds with the best 
therapeutic efficacy while minimizing any drug safety issues. But these quantities are 
challenged only late in the progression path. Discovering that the mechanism
5
 has an 
inherent side effect, or that the target has minimal potency with respect to a disease, or 
that a compound is unsafe to be used in humans’ results in going back to the beginning of 
the progression path and finding new molecules or new targets.  
   In order to find the key molecule to begin testing in a clinical setting, a tremendous 
amount of semi-structured pharmacological assay data is generated. The information 
surrounding an assay including assay type, target name, target class, assay medium, assay 
experimental information is stored in relational database tables. In the context of this 
study, this information/metadata surrounding the assay will be referred to as ‘assay 
annotation’.  
Due to lack of foresight or inconsistencies in how the assay data has been captured 
over time, the annotation surrounding a particular assay is often incomplete. In addition 
to absent annotation, existing protein name and assay information do not utilize a  
standardized set of terms for each field, making retrospective querying of the data subject 
to ontological and semantic ambiguities.  With such a vast amount of data (tables with 
nearly 1 Billion records), retrieving and interpreting specific data as well as application of 
                                                          
5
 Mechanism of action: Specific biochemical interaction through which compound produces its 
pharmacological effect. 
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sophisticated and broad informatics techniques is dependent on complete, accurate, and 
consistent assay annotation.  
Having the assay data fully annotated allows scientists to search against a 
compound’s history and similar compounds histories for activity against specific targets. 
Capturing historic internal and external data in a structured manner enables retrospective 
and comprehensive querying of these data. This will help identify promising compounds 
that allow a scientist or a researcher to bypass the earlier stages of the progression path, 
thus challenging a therapeutic hypothesis sooner, developing a better understanding of a 
disease state or generating a better understanding of the mechanism of action by 
correlating target activity to an observed toxicity. This will reduce costs and time and 
avoid going down the progression path with compounds that are doomed to fail or on 
targets that will never be effective. This gives rise to an opportunity of improving the 
efficiency of drug discovery, by creating structured annotation around historic 
pharmacological assay data. 
This research studies how existing data mining, information extraction and retrieval 
methodologies can be used to accurately annotate existing disparate data sources in an 
automated and accurate fashion. Text mining methods can potentially create structure and 
annotation around legacy biochemical experiments, enabling better interpretation of 
current experiments and the potential repurposing of historically synthesized and tested 
compounds. 
The remainder of the paper is organized as follows. Following a survey of the 
existing literature in text mining applications and methods in the pharmaceutical domain, 
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the setting, data and methods of this study are described. After presentation and 
discussion of results, the paper concludes with possible avenues for future research. 
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2. Literature Review: 
This section provides an overview of the applications of text mining and information 
extraction in the pharmaceutical domain and some of the solutions that are available. 
Some of the projects discussed in this section have implemented text analytics and 
Information extraction techniques to retrieve protein-protein interaction from biomedical 
data.  While this study does not delve into protein-protein interactions, these articles 
provide some background on popular information extraction techniques that have been 
utilized in the biomedical domain with semi-structured and unstructured data sources. 
This section also discusses some proprietary solutions that can be applied to leverage the 
value of internal and external data-sources and to inform and improve drug discovery.  
The pharmaceutical industry is inundated with massive amounts of chemical, 
biological and clinical data, composed of both specialized proprietary data as well as 
other open-source databases (PubChem
6
, PubMed
7
). Integrating various proprietary 
experimental data with open source biological, chemical and clinical databases like 
PubChem and PubMed would provide users with a unified view of all the data available 
and would enable more robust data analytics that would inform the drug discovery 
process.
                                                          
6
 Website: https://pubchem.ncbi.nlm.nih.gov/ 
7
 Website: http://www.ncbi.nlm.nih.gov/pubmed 
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 Several organizations curate and structure biological, chemical and medical data. 
Thomson Reuters
8
 for example, structures and annotates known portions of clinical 
pipelines of pharmaceutical companies, as a competitive intelligence tool. Aureus
9
, a 
provider of database and informatics solutions to pharmaceutical companies, structures 
and annotates published compounds and their biological activities, to enable confident 
drug discovery decisions. But, these databases are created by applying a combination of 
proprietary data mining and manual review, and are focused on specific publicly 
available data sources. This study focuses on applying text mining tools to leverage 
proprietary internal data sources. There are several open source and proprietary solutions 
are available in the market that help organizations integrate and utilize their data 
effectively such as Palantir
10
, Pipeline Pilot
11
 and Linguamatics
12
. More information 
about the pharmaceutical text mining solution Linguamatics, which was available for use 
through the course of this study is provided later in the section.  
Apart from the state of the art solutions available in the market, there have been other 
research projects that have been conducted in performing text mining and information 
extraction with biomedical, chemical and pharmacological data. These techniques mainly 
focus on entities like genes, proteins and the interactions and relationships between these 
entities implementing strategies like Parts of Speech Tagging, Named Entity Recognition, 
Tokenization, etc. (Fluck, Zimmermann, Kurapkat, & Hofmann, 2005; Hahn, Cohen, 
                                                          
8
 Website: http://cmr.thomsonreuters.com/services/programs/discovery/ 
9
 Website: http://www.aureus-sciences.com/ 
10
Website: http://www.palantir.com/  
11
 Website: http://accelrys.com/products/pipeline-pilot/ 
12
 Website: http://www.linguamatics.com/ 
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Garten, & Shah, 2012) . A review of these techniques informed the design of this study, 
to create high performing text mining models.   
Named Entity Recognition (NER) is an Information Extraction technique that has 
been implemented successfully in retrieving protein information from biomedical text, 
and hence was reviewed to identify a feasible approach to implementing an automated 
solution to add structure to the existing assay data.  This section provides an overview of 
Named Entity Recognition, and the various types of NER techniques that have been 
implemented by different projects in this domain. Some of the problems associated with 
identifying biological objects in written text make NER a difficult process. These 
difficulties arise due to various factors like lack of uniform naming conventions, use of 
many synonyms and homonyms in the text and also the fact that names of biological 
objects often consists of multiple words, Greek letters and special characters Consider for 
example, the protein name  
‘CCAAT/enhancer binding protein (C/EBP), alpha’ 
(Leser & Hakenberg, 2005; Fluck, Zimmermann, Kurapkat, & Hofmann, 2005) 
The NER process can be viewed as containing three different aspects: identifying the 
entity, assigning a category to this entity and normalizing the representation (in case 
synonyms exist) (Leser & Hakenberg, 2005). For example, NER identifies the acronym 
“MAPK” in the text of the document as an entity and classifies it as a kinase. “Mitogen-
activated protein kinase” and “MAP Kinase” are synonyms of “MAPK”. All these 
synonyms will be represented by a preferred term, which could be one of these 
synonyms. 
13 
 
 
The fundamental approaches to Named Entity Recognition tasks may be defined as: 
Dictionary based, Rule based, Classification based and Sequence based. Dictionary based 
NER is the process of exactly matching dictionary terms to entries in the text (Leser & 
Hakenberg, 2005). These dictionaries are derived from existing biomedical, clinical or 
chemical databases, like Uniprot
13
. These systems provide high precision but low recall, 
as dictionary entries search the text for exact matches. ProMiner (Hanisch, Fundel, 
Mevissen, Zimmer, & Fluck, 2004) is an example of a system that has implemented 
Dictionary Based NER to extract gene names by generating and curating a synonym 
dictionary and identifying the object given a text corpus(test cases in BioCreAtIvE
14
 
competition). This system has provided encouraging results (F-measure:>0.78).  
Using a dictionary based system does not require an annotated corpus. It also allows 
for each instance to be identified by a concept identifier, which can prove to be 
advantageous in reducing the effort required for term normalization in cases where each 
instance has multiple synonyms. For example, MAPK, Map Kinase and Mitogen-
activated protein kinase can all be identified by the unique id from the UniProt Database. 
A drawback of using a dictionary based approach is that incorporating fuzzy 
algorithms to match dictionary entries to improve recall, can lead to over-fitting, wherein 
the algorithm performs well only for known data. 
The rule based approach to NER is the process of identifying specific rules to extract 
entities like protein names. For example, a rule could be defined based on surface clues, 
wherein all terms that start with a capital letter could be considered as candidates for a 
                                                          
13
 Website: http://www.uniprot.org/ 
14
 Website: http://biocreative.sourceforge.net/ 
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protein name.  There are several systems that are supported by manually-encoded rules 
(Blaschke & Valencia, 2002; Ono, Hishigaki, Tanigami, & Takagi, 2001; Mooney & 
Bunescu, 2005; Jiang, Information Extraction from Text, 2012). The SUISEKI 
Information Extraction system (Blaschke & Valencia, 2002) for example uses a set of 
rules (called frames) derived from morphological, syntactical and contextual information 
to detect protein names and interaction from scientific texts.  
The research conducted by (Ono, Hishigaki, Tanigami, & Takagi, 2001) used a 
combination of dictionary based and rule based extraction to extract protein-protein 
interaction from biomedical text. First, the protein names were identified using a 
dictionary of manually constructed protein names. The sentences containing atleast two 
protein names were extracted using two rules based on parts of speech. These sentences 
were then parsed with a pattern matching rule to recognize the protein-protein interaction. 
This rule is based on the arrangement of protein names, prepositions and keywords that 
represent the relationship between protein names. This study was conducted for yeast and 
E.coli proteins (due to the availability of well-maintained protein databases), and 
obtained high precision (yeast: 94.3% and E.Coli: 93.5%) and recall rates (86.8% and 
82.5%).   
Rule based extraction systems can provide very high values of precision (Leser & 
Hakenberg, 2005; Ono, Hishigaki, Tanigami, & Takagi, 2001). But a major drawback of 
rule based extraction is the human effort involved in deducing and encoding patterns 
from a training dataset. This approach will be likely to maximize performance for known 
data points, but perform less effectively with respect to unseen data. The more specific a 
rule or a pattern is, the lower the value of recall.  
15 
 
 
Classifier-based named entity extraction techniques involve the use of a gold standard 
dataset to train a classifier model to classify single word occurrences or multi word 
phrases into specific categories(for example: “gene” or “not gene”).  Leser & Hakenberg 
(2005), discuss three main classifier models, the Naïve-Bayes classifier, Support Vector 
Machines and Hidden Markov Models.  
The Naïve-Bayes classifier is a simple, powerful and robust classifier with a strong 
independence assumption. In other words, the presence or absence of a particular feature 
has no effect on the presence or absence of other features. The probability of an instance 
belonging to a particular class is calculated based on the presence or absence of features 
with respect to a particular class.  Classification can be performed based on properties of 
words or word phrases such as word length, letter frequency etc. 
 Support vector machines (SVM) are non-probabilistic linear classifier algorithms that 
can be used effectively in entity extraction tasks. SVM’s use learning algorithms that 
analyze data and recognize patterns to perform classification. SVM’s used a labelled 
training dataset to build learning models and assign new instances to one of the labels 
(Support Vector Machines, 2014).    
Hidden Markov Models use the sequence in which features appear in text (order of 
words in a sentence) to predict the most probable sequence of events for a sentence 
(Leser & Hakenberg, 2005).   This prediction is performed by aggregating statistical 
information from labelled examples. 
The Leser & Hakenberg (2005) article states that classification based approaches 
have proven to be one of the most popular approaches to performing entity recognition. 
16 
 
 
Classification approaches take into account just the features that are generated by a word. 
They do not take the order of words into account. But a drawback of using classification 
approach is that quality of prediction is dependent on the features, and the best 
combination of features should be chosen empirically.  
In the context of this study, identifying specific target information from the available 
assay data, or extracting and understanding the import of an experiment based on terms 
occurring in the assay data can be viewed as an entity recognition task. Extracting target 
names, or target class or other target specific information based on the occurrence of 
specific terms in the assay data can benefit from the use of dictionary based NER.  Being 
able to extract the import of an experiment based on terms that occur in the available data 
can be performed using rule based or classifier based NER.  
This review suggests that classifier based approaches would provide more robust and 
reliable results. The classifier models can potentially be extended to larger datasets, and 
the performance of these classifiers can be tuned to provide highly accurate results. 
However, as mentioned earlier, the performance of the classifier is greatly dependent on 
the features selected.  
Tokenization is the process of breaking up a stream of text into words or other textual 
units called tokens which are used further in text processing and mining (Fluck, 
Zimmermann, Kurapkat, & Hofmann, 2005; Trim, The Art of Tokenization, 2013). Jiang 
& Zhai (2007) studied the impact of various tokenization strategies on biomedical 
information retrieval. The TREC biomedical text collection was used for ad-hoc retrieval 
and studied the retrieval performance for different tokenization heuristics. First, non 
17 
 
 
functional characters like “=” or “#”, punctuations (which do not occur in gene names) 
were removed. Three different strategies were employed to replace the special characters 
occurring within the gene names. The first method was to replace special characters with 
hyphens, the second was to replace them with spaces and the third was to remove them 
completely. Stemming and stopword removal was also performed on the three datasets, 
and retrieval was evaluated based on Mean Average Precision
15
 (MAP). Results showed 
that tokenization improved performance by upto 96%. Stemming on the other hand, was 
not effective for all queries. Stopword removal did not improve performance or improved 
it very slightly. This study helped inform the feature selection process for classification 
models by implementing methods like stemming, stopword removal etc., to improve the 
performance of the classifier.   
Information extraction systems are typically evaluated by comparing results with gold 
standard datasets which consists of a set of domain specific, manually annotated 
documents (Leser & Hakenberg, 2005; Jiang, Information Extraction from Text, 2012; 
Mooney & Bunescu, 2005). The evaluation metrics for NER systems and Information 
Extraction systems in general are typically Precision
16
, Recall
17
 and F-measure
18
. 
                                                          
15
 Mean Average Precision(MAP) for a set of queries is the mean of the average precision values for 
each individual query.  
     
∑        
  
   
  
; Where Qn is the number of queries. 
16
 Precision = 
              
                              
 
17
 Recall=
              
                             
  
18
 F-Measure: Harmonic mean between precision (P) and recall(R). 
= 
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Accuracy
19
 is another metric that is used to evaluate system performance, and this metric 
will be used through the course of this study. 
One commercially available text mining platform in the pharmaceutical domain is the 
Linguamatics I2E software. Linguamatics can be used in Text Mining applications to 
query both internal proprietary data-sources and publicly available sources. This software 
was available for use in this study, and hence an application of this software is reviewed 
in this section. This provides an understanding how the software could potentially be 
used in this study and in further work around this data.  
 The Linguamatics I2E software was used to extract protein-protein interactions from 
MedLine abstracts (Bandy, Milward, & McQuay, 2010). The Medline index was queried 
using four different types of queries to extract information. The first query used a precise 
linguistic pattern using relationships that are relevant to protein-protein interactions. This 
query pattern provided results with “high precision”. The second query provided a 
“higher recall”, by querying for a precise linguistic pattern, but allows any verb. The 
third query retrieved proteins appearing within a sentence structure, and hence provides 
results with much “lower precision” and “higher recall”. The fourth query returned 
proteins appearing within the same document, and hence results in the “highest possible 
recall”, but “lowest precision values”. Each of these strategies resulted in high quality 
results.  
The goal of the research described here is to extract relevant assay information from 
existing experimental data using a Naïve-Bayes classifier to train and test classification 
                                                          
19
 Accuracy= 
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models. This study was performed in consultation with scientists who wanted to improve 
the annotation of the experimental data. These scientists served as domain experts, who 
provided an understanding of how this data could be used to improve the drug discovery 
process. They helped in the creation of the subset of data used for this study. They 
reviewed the datasets, evaluated the classification results and helped identify strategies to 
improve the performance of the classifier. This work brought about some structure and 
uniformity in the annotation and served as a first step for the scientists to leverage 
existing experimental data to improve and inform drug discovery. 
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3. Research Overview 
3.1 Information Infrastructure 
This section provides more detail about the information infrastructure that is used in 
this study. An overview of the databases that records the assay information is provided, 
along with specific information about specific data fields that are used in this study. 
 
Figure 2: High Level Schematic of Assay Information 
 
 
21 
 
 
Figure 2 shows a high level representation of the information infrastructure for assay 
data that is used in this study. This data is primarily stored in two relational databases, 
referred to as Results_DB and Protocol_DB.  These databases have been in use for more 
than a decade and over the years have captured vast amounts of assay information.  
RESULTS_DB: 
The results of experiments are stored in a relational database (Results_DB). The data 
generated from a single assay protocol generally resides in a single table that corresponds 
to that particular protocol. Other descriptive information surrounding the assay protocol 
is recorded in this database as well. The information that is most relevant for this study 
and that was extracted to perform the study are fields that describe the human readable 
assay name, the assay description and the assay medium. Generic examples (obtained 
from PubChem
20
) are provided with the descriptions below. 
Name: The human readable assay name will be referred to as Name. This field 
corresponds to a short name that refers to the assay, for example  
“MAPK Signaling Pathway Screen” 
Description: This field refers to a short description about the assay. This field will be 
referred to as Description throughout this study. Consider the example provided above. 
The corresponding description for this assay would be  
“A functional RNAi screen for regulators of receptor tyrosine kinase and ERK 
signaling” 
                                                          
20
 Link from which the assay example was obtained from: 
http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=686943 
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Medium: This represents the medium in which the assay is conducted and is derived 
from the original assay protocol. For example, an assay could be conducted in a Cell-free 
medium or in Cellular media.  
The database captures more information about an assay, including more specific 
biological information such as the organism involved in the assay if any, and assay type 
as well, but they were judged to be unnecessary for this study.  
 PROTOCOL_DB: 
Experimental protocols and some annotation about each assay are stored in tables in 
the relational database Protocol_DB. This database contains some information associated 
with the target of the assay such as target name and target class which were not used in 
this study. This database houses the experimental procedure, in XML protocol files. In 
many cases, each assay is associated with multiple versions version of XML protocol 
files. It is assumed that the latest version of the XML protocol file, has the most complete 
and updated information around a particular document. 
Scientists identified fields in the XML protocol file that were most likely to contain 
relevant information concerning an assay. These included the Abstract, Rationale and 
Procedure fields, which were examined to be used as sources to derive assay annotation. 
However, the scientists determined the procedure field (described below) to be the best 
source for this study.  
Procedure: This field that provides the steps that were performed to conduct the 
experiment. 
23 
 
 
The experimental data that resides in Results_DB is linked back to the experimental 
protocol in Protocol_DB. 
SUMMARY_VIEW: 
 Summary_view represents the aggregated view of assay information sourced from 
both Protocol_DB and Results_DB. This view contains around 1 Billion records and 
serves to capture all experimental information along with the corresponding assay 
annotation from both the databases. Ideally a scientist or any other end user looking for 
information associated with a particular assay or wanting to analyze the experimental 
information in aggregate should be able to query this view to retrieve the information that 
they need.  
Unfortunately, as it currently exists summary_view is not a complete and annotated 
view of the assay data. This can be attributed to many factors, some of which have been 
described in the Introduction. In a number of cases summary_view is missing critical 
target information such as assay medium, target/protein class, target name and other 
assay specific information which would help a scientist easily distinguish relevant and 
non-relevant assays. In addition, existing protein name and assay information do not 
conform to a uniform dictionary for each field. This results in ambiguity while querying 
the database.   
This study attempts to improve the annotation surrounding the assay information by 
implementing various text mining technologies to automatically extract metadata from 
the various assay data sources available. In the long run, the results of this study will help 
identify viable text and data mining techniques that can be applied to improve the 
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structure and annotation of Summary_view. Thus the scientists will be able to utilize this 
data effectively in other informatics and analytical applications (like predictive analytics) 
to maximize the value of this data, thus improving the efficiency of the drug discovery 
process.  
3.2 Creation of a Data Subset 
Summary_view, which provides an overall representation of all the assay data 
available, contains nearly 1 Billion records. Working with the entire dataset would be 
beyond the scope of this research. This section describes the subset of data used for the 
study and the rationale behind using this it.  
As described in the Introduction, assays can be performed in different media: 
 Cell-free 
 Cell-based or Cellular component based 
 In-vivo 
Discussions with the scientists revealed that being able to classify assays into 
categories based on the assay medium could serve as a first step in bringing about some 
structure to the data. For example, this categorization helps in distinguishing a target-
centric
21
 assay from a more phenotypic assay
22
 which adds value in understanding what 
the activities of a compound are and what behavior it induces. Three categories
23
 of 
                                                          
21
 Target Centric Assays are those that are performed around a single target or a set of targets 
22
 Phenotypic assays are conducted to identify substances that alter the phenotype of a cell or organism 
in a desired manner. 
23
 Refer to Appendix for definitions of these categories 
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assays (Cell-free, Cellular and In-vivo) were defined based on the medium in which the 
experiment was performed. 
The field Medium, in the Results_DB captured this information, but it was not 
available for all the assays. The dataset that was used in this study was a subset (Subset 1) 
of the larger data store. It should be noted that, Subset 1 was not a random sample of the 
larger dataset, but was instead a carefully consolidated dataset. Subset 1 was created by 
querying Results_DB and Protocol_DB, with terms judged (by the scientists) to be 
relevant to the categories Cell-free, Cellular and In-vivo, to extract assays belonging to 
these categories. Subset 1 contained the name, description and the XML protocol file of 
the assays. The limitations associated with this dataset will be discussed in further detail 
in the Discussion Section. 
The Methods contains a more detailed description of this dataset, along with the 
number of records per category and the tasks that it was used for.  
3.3 Study Goals 
The overall goal of this study is to improve assay annotation by implementing a 
naïve-Bayes classifier. Based on Subset 1 described in the previous section, these goals 
were revised to fit the scope of the current study. These goals are described below:  
 Review Subset 1 with the scientists to identify any misclassified records in the 
data, and refine Subset 1 if needed and utilize this dataset for classification. 
The tasks performed to accomplish this goal will be referred to as Task 1. 
Task 1 includes the use of automated information extraction techniques to 
identify specific terms that indicated whether records were misclassified or 
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not. This helped identify and eliminate misclassified records that resulted in a 
cleaner dataset.  
 Build Naïve-Bayes classifier models to train and test on the data from Subset 
1 to automatically categorize the assays into different categories with high 
accuracy. The tasks performed to accomplish this goal are referred to as Task 
2. While the most of the methods discussed in the Literature Review have 
used F-measure as an evaluation metric, this study used accuracy as the 
evaluation metric.  
Accuracy of classification in this study can be defined as: 
                                                                                           
                                                                        
 
While precision and recall are important indicators of system performance, for this 
particular application, the most important outcome is the accuracy of the classifier. This 
reflects the need to be able to use the assay annotation for further analytics to better 
understand the activity of a compound or to potentially inform and improve target 
selection or to quantify the selectivity of a compound for one target over the other. These 
applications require the data used to be highly accurate, and hence the classification must 
produce highly accurate results. The models were refined based on strategies discussed in 
the Literature review, to improve the performance of the model to obtain high values of 
accuracy. 
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4. Methods: 
4.1 Datasets 
The datasets used in this study are derived from Subset 1 described in the previous 
section. Table 1 below provides a description of each of the derived datasets, including 
the tasks it was used for, total number of unique records and the number of unique 
records per category (Cell-free, Cellular, In-vivo) of the dataset. Dataset B, was derived 
from the XML Protocol file (Dataset C) after Task 1 had been completed.  
As shown in Table 1, the datasets do not contain an equal distribution of records across 
the three categories. As mentioned in the Research Overview, Subset 1 was compiled by 
querying the database for records that satisfied specific conditions, and hence was not a 
random sample of the larger dataset. However, it was not possible in the given timeframe 
to verify the actual distribution of the full dataset, hence no statement can be made as to 
the representativeness of Subset 1, nor of datasets derived from it.  
Duplicate records were eliminated in this study and only unique and complete records 
were used to train the classifier. 
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Table 1: Description of Datasets Used 
Dataset  Fields used Description Used 
in 
Total 
Number of  
unique 
Records 
Unique 
Records/Category 
A Name & 
Description 
Includes the 
assay name and 
description 
obtained from 
Results_DB. 
Task 1 
and 
Task 2 
811 292: Cell-free 
347: Cellular 
172: Invivo 
 
B Procedure The procedure 
extracted from 
the XML file  
Task 2 1683 166: Cell-free 
331: Cellular 
1209: Invivo 
 
C XML Protocol 
File 
The entire 
XML assay 
protocol file 
Task 1 2903 188: Cell-free 
331: Cellular 
2384: Invivo 
 
4.2 Tools Used 
The tools and technologies used during the course of this study are listed below: 
 Linguamatics: 
The I2E text mining platform provided by Linguamatics (Linguamatics Ltd, 
2014) was available for use through the course of this research. This tool was 
used in Task 1 to identify and extract metadata from the available assay data 
 LightSide: 
LightSIDE is an open source text mining and machine learning toolkit 
(LightSide, 2014). This tool was used in Task 2 to train and test classifier 
models for text classification. 
 Python:  
The programming language Python was used to format the datasets before 
uploading into Linguamatics and LightSIDE. The open source Python library, 
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BeautifulSoup
24
 was also used to extract the procedure field from the protocol 
file. 
4.3 Process 
Task 1: Use automated information extraction techniques to retrieve metadata from 
the text. 
The goal of this task was to use information extraction techniques to validate the 
existing categorization of records in Subset 1. This was accomplished using the 
Linguamatics I2E platform. To build a document index using I2E, ontologies are used to 
search and analyze the text in the documents. 
The Linguamatics ontologies include NCI thesaurus and MeSH terms (among other 
publicly available and proprietary dictionaries). A descriptor or a synonym of a descriptor 
from the MeSH ontology or the NCI ontology is referred to as a concept.  
 Document indexes (using the datasets A & C described above) were created using 
the Linguamatics software. Each record in these datasets was represented as an individual 
document in the index identified by its unique id. These indexes were queried using the 
MeSH and NCI ontologies to extract relevant metadata (that is, terms that could indicate 
what type of assay was performed) that would help in identifying the assay medium.  
The purpose of this step was to discover the occurrence of any concept that might 
indicate a record with that term was misclassified. For instance, the assays identified as 
Cell-free should have minimal cellular descriptors. The occurrence of a cellular concept 
                                                          
24
 http://www.crummy.com/software/BeautifulSoup/ 
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in an assay in the Cell-free category would raise a flag. Thus the Cell-free index was 
queried to find the occurrence of any cellular concept. This would trigger a manual 
review of the descriptor/concept and the particular assay to identify if it was a 
misclassification or not. Thus, Datasets A and C were reviewed by the scientists to rectify 
or eliminate misclassified instances.     
Task 2: Build Naïve-Bayes classifier models to train and test on the data from Subset 
1 with high accuracy. 
 The goal of this task was to build a Naïve-Bayes classifier model that could 
automatically classify the assays into the three categories with high accuracy. Datasets A 
& B were used to build Naïve-Bayes classifier models using LightSIDE. As an initial 
step to assess and understand the performance of the Naïve-Bayes classifier, the model 
was built with Dataset A. This dataset was uploaded in the form of a CSV file containing 
text fields with the assay names and descriptions, and the corresponding assay category. 
The feature plugin in LightSIDE was used to extract unigram features, removing 
stopwords and punctuations (like colon, semi-colon, hyphen, comma, period etc.). It was 
assumed that the most descriptive features in the dataset would occur atleast 5 times and 
hence the threshold for term frequency was set to 5.  
The features that were extracted were used to train a classification model using 20- 
fold cross validation.  This model provided a high value for accuracy when tested on 
Dataset A (92.6%), but there were many false positives with respect to the Cell-free 
category. The confusion matrix is provided in Table 2 below: 
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Table 2: Confusion Matrix for Initial Run with Dataset A 
Actual / 
Predicted Cell-free Cellular InVivo 
Cell-free 286 4 2 
Cellular 50 294 3 
InVivo 0 1 171 
 
In order to minimize the number of misclassifications, the feature set was reviewed 
by the scientists to identify non-descriptive features in the Cell-free category. Terms 
including full, curve and binding were found to have a high precision(>0.7) and relatively 
low recall(<0.3) with respect to the Cell-free category, however these features occurred in 
the Cellular category as well, which resulted in the misclassification of a few Cellular 
records as Cell-free. 
Using the trained model, LightSIDE assigned the predicted categories for Dataset A, 
thus allowing further analysis of the misclassified instances. This was beneficial, as it 
helped identify one record that actually belonged to the Cellular category, but had been 
wrongly categorized as In-vivo. This misclassification was rectified, and that record was 
assigned to the Cellular category. 
Based on the initial run described above, a few different techniques for feature 
generation were proposed to improve the accuracy of the classifier. The basic classifier 
model was built with unigram features and removal of stopwords, punctuation, numbers 
and decimals. In addition to this, the variations mentioned below were tried out one by 
one, and the performance of the classifier was evaluated using 20-fold Cross Validation 
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for each of these variations. Below listed are the variations to the basic model performed 
on Dataset A 
1. Generation of Bigram features 
2. Stemming 
3. Removal of the terms full, curve and binding. 
4.  Using Regular expressions to extract descriptive features. Morphemes that were 
thought to be highly indicative features with respect to the Cellular category were 
identified. An example of a regular expression pattern used in refining the 
features is (\w+) cyte, to retrieve any word that contains cyte. 
Table 3 presents the classification models generated using Dataset A. The basic 
classification model includes the initial set of features: unigrams, removal of stopwords 
and punctuation, and removal of non-descriptive features such as numbers 
Table 3: Classification Models generated using Dataset A 
Classification Model Features Generated 
1 Basic features 
2 Basic features and removal of full, curve 
and binding 
3 Basic features and stemming. 
4 Basic features and stemming and the 
removal of stemmed features, full, curv 
and bind 
5 Basic features and Bigrams 
6 Basic features and Bigrams and removal 
of binding and full-curve. 
7 Basic features and use of regular 
expressions 
8 Basic features and use of regular 
expressions and removal of full, curve and 
binding 
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Dataset B contains the procedure field from the XML protocol file, and consists of 1706 
records with 166 records in the Cell-free category, 331 records in the Cellular category 
and 1209 records in the Invivo category.  The basic classification model using this dataset 
was generated with unigram features, removal or stopwords and punctuation. These are 
referred to as basic features in Table 4. Note that unlike Dataset A, numbers were not 
removed for the basic model with Dataset B. The procedure field is much longer than the 
brief assay name and description fields, and hence there were more features generated in 
Dataset B than in Dataset A. Non –descriptive features were not identified and eliminated 
in the basic model, as the number of features generated made manual review of these 
features impractical.  
Table 4: Classification Models generated using Dataset B 
Classific
ation 
Model 
Features Generated 
9 Basic Features 
10 Basic Features and stemming 
11 Basic features and bigrams 
12 Basic Features, bigrams and stemming 
13 Basic Features and removal of numbers and decimals 
 
The results of these classification models are provided in the next section. 
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5. Results 
The accuracy of each model described in Tables 3 and 4 is presented in Tables 5 and 
6. 
Table 5: Classification Results for models described in Table 3 
Classification 
Model 
Accuracy 
1 92.8% 
2 93.1% 
3 92.7% 
4 92.4% 
5 92.2% 
6 91.9% 
7 92.7% 
8 92.9% 
 
Table 6: Classification Results for Models Described in Table 4 
Classification 
Model 
Accuracy 
9 89.5% 
10 88.2% 
11 86.3% 
12 85.6% 
13 90.3% 
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Dataset A with more concise name and description fields consistently yielded better 
performance than the longer procedure field. The highest value of accuracy obtained with 
Dataset A, was 93.1%. The high performing model included unigram features, without 
stopwords, punctuation and the non-descriptive features full, curve and binding. The 
lowest accuracy obtained was 91.9%, with the use of unigram, bigram features along with 
stemming and removal of stopwords, punctuation and non-descriptive features binding, 
full and curve. 
For Dataset B, the highest value of accuracy obtained was 90.3%, by the classification 
model with unigram features, without stopwords and punctuation and non-descriptive 
features like numbers and decimals. The lowest value of accuracy obtained was 85.6% by 
Model 12, which used unigram, bigram and stemmed features along with stopword and 
punctuation removal. 
Certain feature generation techniques lowered performance in both the datasets. The use 
of bigrams lowered performance in both the datasets (Model 5, Accuracy 92.2% and 
Model 11, Accuracy 86.3%). The use of stemming with unigram features did not impact 
performance in Dataset A (Model 3, Accuracy 92.7%), but lowered performance in 
Dataset B (Model 10, Accuracy 88.2%). The use of regular expressions, did not improve 
the performance of the classifier as well (Model 7, Accuracy 92.7% and Model 8, 
Accuracy 92.9%). 
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6.  Discussion 
This study was conducted to evaluate whether various text mining and information 
extraction techniques could be used to classify and structure experimental assay 
information. Scientists helped create a subset of data (Datasets A, B and C) as described 
in the Methods section, which was used to train and test a Naïve-Bayes classifier. The 
results obtained are encouraging and suggest that this method can be applied successfully 
to a larger dataset. This section describes the impact of stemming, feature removal and 
regular expressions on the classification results. This is followed by an overall discussion 
of the value afforded by text mining approaches to structure experimental assay data 
while addressing some concerns with respect to the distribution, as well as extensibility 
of the classification models.   
 Impact of Feature Removal on Classification 
Certain features were identified as being non-descriptive. These features occurred 
many times in a particular category, but had little import with respect to that 
category. Model 2 was created by eliminating the non-descriptive features – 
binding, full and curve. This model achieved the highest value of accuracy for 
Dataset A, but it did not reduce the number of false positives with respect to the 
Cell-free class as expected (as seen in table 7). This suggests the presence of other 
non-descriptive features. Further analysis and identification of these features 
would have potentially improved the performance of the classifier, however the 
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number of features made this impractical. In addition, removal of too many 
features could have resulted in an over-fitted model, which would limit the 
extensibility of the model. This strategy was not employed with Dataset B, 
because the number of features made manual analysis and identification of non-
descriptive features with respect to each category unfeasible. 
Table 7: Confusion Matrix for Dataset A, Model 2 
Accuracy: 93.1% 
Actual/ 
Predicted 
Cell-free Cellular In-vivo 
Cell-free 286 4 2 
Cellular 48 296 3 
In-vivo 0 0 172 
 
 Impact of Regular Expressions on Classification 
Scientists identified a few biological terms that could serve as good features for a 
particular category. For example, cell types (like adipocyte, lymphocyte) were 
found to be useful in identifying an instance as Cellular. Unfortunately, these 
specific features that occur in Cellular assays were not initially extracted as they 
occurred at a low term frequency.  
The use of the regular expression ‘(\w+)cyte’ made it possible to extract all terms 
ending with the morpheme ‘cyte’ without having to reduce the threshold of term 
frequency. But the use of regular expressions did not have much impact on the 
performance of the classifier. Although, the features that ended with ‘cyte’ were 
extracted, it did not add to the classification power of the model, and the accuracy 
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did not improve. The confusion matrices along with the accuracy obtained for 
model 7 and model 8 are provided below in Table 8 and Table 9 respectively. 
 
Table 8: Confusion Matrix for Dataset A, Model 7 
 
Accuracy: 92.7% 
Actual\ 
Predicted 
Cell-free Cellular In-vivo 
Cell-free 286 4 2 
Cellular 49 295 3 
In-vivo 0 1 171 
 
 
Table 9: Confusion Matrix for Dataset A, Model 8 
 
Accuracy: 92.9% 
Actual\ 
Predicted 
Cell-free Cellular In-vivo 
Cell-free 285 5 2 
Cellular 42 298 7 
In-vivo 0 1 171 
 
 
 Impact of Stemming on Classification 
Stemming of features did not have much impact on the accuracy in Dataset A 
(confusion matrix presented in Table 10), and reduced the accuracy in Dataset B 
(confusion matrix presented in Table 11). On one hand, stemming down to the 
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root helped identify new features that otherwise were under the threshold for term 
frequency (For example, the stemmed feature intravenous was extracted, whereas 
the more specific features intravenous and intravenously were individually not 
extracted from the dataset. On the other hand, stemming undermined the value of 
certain descriptive features like rat (which is less likely to occur in the In-vivo 
category) versus rats (which is more likely to occur in the In-vivo category).  
Table 10: Confusion Matrix for Dataset A, Model 3 
 
Accuracy: 92.7% 
Actual\ 
Predicted 
Cell-free Cellular In-vivo 
Cell-free 287 3 2 
Cellular 49 295 3 
In-vivo 0 2 171 
 
Table 11: Confusion Matrix for Dataset B, Model 10 
Accuracy: 88.2% 
Actual\ 
Predicted 
Cell-free Cellular In-vivo 
Cell-free 160 6 0 
Cellular 45 263 0 
In-vivo 122 25 1062 
 
 
The relatively high values of accuracy obtained for the classification models for both the 
datasets are encouraging, but these values of accuracy did not correlate with the 
probability score for classification of the instances. There was no ambiguity or very little 
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random chance in these classifications, most instances had near perfect probability 
scores. For example, Model 2 which obtained the highest accuracy, had probability 
scores greater than 0.7 for 788 out of 811 records. This meant that more than 97% of the 
predictions made were very strong. Unfortunately, this includes misclassifications as 
well. Out of 48 false positives with respect to the Cell-free category in model 2, only 6 
instances had a probability score less than 0.72.  While this can be attributed to the fact 
that the features generated were few and hence were strong descriptors for classification, 
it does undermine the application of this data in further analytics to inform drug 
discovery. A model that results in very strong assertions of false positives or false 
negatives, will create more noise and ambiguity around the historical assay data which 
can further impair the drug discovery process.  
There are a few limitations associated with the training dataset used. As mentioned in the 
Research Overview, Subset 1 was not a random sample of the larger dataset, but instead 
was created by querying the database based on certain conditions proposed by scientists 
to find records that belong to the three different categories. Records in the datasets used 
are unevenly distributed across the categories. This cannot be assumed to be 
representative of the larger dataset, because the subset was not created by random 
sampling. The disparity in the subset of data used for this study was not rectified, as the 
distribution of the larger dataset was unknown and estimating the distribution in the 
larger was not feasible given the timeline of this study.  
Apart from building classification models, automated text mining techniques added 
value in identifying descriptive and discriminating features with respect to each category. 
For example, study is always used in terms of an In-vivo experiment, whereas a Cellular 
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or Cell-free experiment is called an assay; the environment in which a Cell-free 
experiment is conducted is always referred to as media, but in a Cellular experiment it is 
referred to as a solution. These features helped scientists develop a better understanding 
of the existing data and how this data is recorded.  
Linguamatics also proved to be an effective way to explore the existing data as well. 
For this research, using Linguamatics was an efficient way to validate the subset of data 
curated, which helped provide reliable training datasets for classification. Furthermore, 
there is potential for a tool like Linguamatics to be used effectively in further research 
around this data, specifically to mine the available data for other experimental metadata, 
like target name and class. 
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7. Conclusion  
The goal of this study was to use automated text mining and information extraction 
techniques to automatically capture some structure in pharmaceutical assay data. The 
results of this study conducted with a subset of assay data have yielded high values of 
accuracy, indicating potential in applying these techniques.  
Structured and annotated data can be further used to inform and improve the drug 
discovery process. Specifically, being able to automatically classify assays into categories 
based on assay media adds value in distinguishing target centric assays and phenotypic 
assays. This will help better understand the mechanism of action for a compound and the 
behavior it induces, which will help identify safer compounds or also help inform target 
selection or . The results obtained are satisfactory, paving the way for further work to be 
carried out in this area. 
Future work carried out will focus on applying the methods described in this study to 
a larger dataset. The use of other fields in Results_DB, Protocol_DB and the XML file as 
data sources to derive assay annotation will be explored. Further mining will be carried 
out to extract other metadata like target name, target class, assay endpoint from the 
available data, using tools like Linguamatics, LightSIDE or other available text mining 
tools.  
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Specifically with respect to target information, a normalized dictionary to represent target 
annotation will be created. This will be useful in deriving target specific information from 
the existing assay data that will help deduce the molecular mechanism of a compound, or 
to quantify the selectivity of a compound for one target over others. Extracting all activity 
with respect to a specific target class will help scientists create structure activity 
relationships (SAR
25
) that will help inform target selections. These various applications 
demonstrate the value of structured assay annotations to improve drug discovery and 
development process.  
  
                                                          
25
 Structure Activity Relationships: the relationship between the chemical structure or 3-dimensional 
structure of a molecule and its biological activity  
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Appendix I 
Glossary of Terms 
Assay: An investigative (analytic) procedure in laboratory 
medicine, pharmacology, environmental biology, and molecular biology for qualitatively 
assessing or quantitatively measuring the presence or amount or the functional activity of 
a target entity (the analyte) which can be a drug or biochemical substance or a cell in 
an organism or organic sample 
Results_DB: Relational database that stores the results of experiments. 
Protocol_DB: Relational database that stores the assay protocol 
Assay Medium: The medium in which the experiment is performed is the assay 
medium. This study identifies three assay mediums: Cell-free, Cellular/cell based and In-
vivo. 
Cell-free: The container in which the experiment is performed contains the 
engineered protein, salts and solvents needed to preserve them.  
Cellular: The entire cell or other cellular components are used in the container in 
which the experiment is performed. 
In-vivo: Assays involve working with Live Animals 
